AstraZeneca
Officials from AstraZeneca provide details of new developments
Published in Healthcare Mergers, Acquisitions and Ventures Week, February 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at AstraZeneca.
Report 1: New phase IIb data from the Disperse2 Study presented at the American Heart Association's Scientific Sessions, assessed the safety and tolerability of the AstraZeneca investigational drug AZD6140 plus aspirin compared with clopidogrel plus aspirin as antiplatelet therapy in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
The primary end point of the study was the incidence of total (major plus minor) bleeding events seen in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Adverse Drug Reactions
Scientists at AstraZeneca detail research in adverse drug reactions in children - Alzheimer Disease
Allon receives approval for phase II clinical trial in Alzheimer-related condition - Analytical Chemistry
New analytical chemistry study findings have been reported from Merck & Co, Inc. - Angiogenesis
New angiogenesis study findings recently were published by researchers at ImClone Systems, Inc. - Animal Cloning
U.S. FDA issues draft documents on safety of animal clones - Anthrax Vaccines
Studies from Medarex, Inc. describe new findings in anthrax vaccines - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
